In a 38-year-old male presenting with fever and altered sensorium, elevated serum glutamic‑oxaloacetic transaminase (AST) 3.5 times the upper limit, persistent thrombocytopenia (platelet count 39–59 × 10⁹/L), dengue IgG positive only, normal erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP), normal prothrombin time (PT) and activated partial thromboplastin time (aPTT), normal sodium, potassium, ionized calcium, and urinalysis without pyuria, and no meningeal signs with stable vital signs, what is the likely diagnosis and what management should be undertaken?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Impression: Probable Encephalitis with Persistent Thrombocytopenia—Likely Dengue-Associated Encephalitis

This patient meets criteria for probable encephalitis and requires immediate lumbar puncture with CSF analysis, neuroimaging (MRI brain preferred), and comprehensive infectious workup including dengue PCR/NS1 antigen testing, while initiating supportive management for both encephalitis and severe thrombocytopenia.

Diagnostic Reasoning

Encephalitis Criteria Assessment

This patient fulfills the major criterion for encephalitis: altered mental status (changes in sensorium) lasting ≥24 hours with no alternative cause identified 1.

He also meets ≥3 minor criteria required for probable encephalitis 1:

  • Documented fever (within 72 hours of presentation)
  • Elevated AST (3.5× normal suggests CNS or systemic inflammation)
  • Altered sensorium qualifies as depressed consciousness

The absence of meningeal signs does not exclude encephalitis, as encephalitis primarily affects brain parenchyma rather than meninges 1.

Dengue-Associated Encephalitis Consideration

The clinical picture strongly suggests dengue-associated encephalitis based on:

  • Dengue IgG positive only indicates past dengue exposure; however, this patient likely has acute dengue with secondary infection (IgG rises early in secondary dengue, often before IgM becomes detectable) 2
  • Persistent severe thrombocytopenia (39-59 × 10⁹/L) is characteristic of dengue and correlates with disease severity 3
  • Elevated AST (3.5× normal) is typical in dengue; severe dengue shows AST levels of 179-1506 IU/L 3
  • Altered sensorium with fever during what appears to be the critical phase of dengue 2
  • Normal PT/PTT despite severe thrombocytopenia suggests peripheral platelet destruction rather than consumptive coagulopathy

Dengue-associated rhombencephalitis develops during the critical phase and manifests as altered sensorium, with only partial neurological recovery expected 2.

Immediate Diagnostic Workup

Priority 1: Confirm Encephalitis

  1. Lumbar puncture with CSF analysis (after ensuring no contraindications):

    • Cell count and differential (≥5 WBC/mm³ supports encephalitis) 1
    • Protein and glucose
    • Gram stain and bacterial culture
    • Dengue PCR/RT-PCR for viral RNA and serotyping 2
    • HSV PCR, enterovirus PCR, Japanese encephalitis serology
    • Note: CSF may show pleocytosis with predominantly mononuclear cells in dengue encephalitis 2

  2. MRI brain with contrast (preferred over CT):

    • Look for multifocal signal abnormalities in brainstem (medulla, pons, midbrain), hippocampi, thalami, and deep white matter 2
    • MRI is superior to CT for demonstrating CNS abnormalities in encephalitis 1

Priority 2: Confirm Acute Dengue

  1. Dengue NS1 antigen (most sensitive in first 5 days of fever) 3
  2. Dengue IgM and IgG titers (repeat testing; IgM may appear later in secondary infection) 3
  3. Dengue PCR with serotyping from serum 2, 3

Priority 3: Assess for Complications

  1. Complete metabolic panel including liver function tests (ALT, ALP in addition to AST)
  2. Hematocrit monitoring for hemoconcentration (plasma leakage indicator)
  3. Coagulation studies already done—normal PT/PTT is reassuring
  4. Chest X-ray and abdominal ultrasound to assess for pleural effusion/ascites (plasma leakage)

Management Algorithm

Immediate Supportive Care

Fluid management is critical:

  • Monitor for plasma leakage (rising hematocrit, pleural effusion, ascites)
  • Judicious IV crystalloid resuscitation if signs of shock develop
  • Avoid aggressive fluid resuscitation in absence of plasma leakage to prevent fluid overload 4

Thrombocytopenia management:

  • Platelet transfusion threshold: Consider if platelet count <20 × 10⁹/L with active bleeding or <10 × 10⁹/L prophylactically
  • Monitor for bleeding manifestations (petechiae, mucosal bleeding, GI bleeding)
  • Avoid IM injections, NSAIDs, and antiplatelet agents

Encephalitis-Specific Treatment

Empiric acyclovir 10 mg/kg IV every 8 hours should be initiated immediately while awaiting HSV PCR results, as HSV encephalitis is treatable and time-sensitive 1.

Seizure management:

  • Antiepileptic drugs if seizures occur (status epilepticus reported in dengue encephalitis) 2

Monitoring for Severe Dengue Progression

Watch for warning signs indicating progression to severe dengue:

  • Persistent vomiting
  • Abdominal pain
  • Mucosal bleeding
  • Lethargy/restlessness
  • Hepatomegaly >2 cm
  • Rising hematocrit with falling platelets

Special Consideration: Refractory Thrombocytopenia

If thrombocytopenia persists beyond day 10-14 of illness (recovery phase), consider immune-mediated mechanism:

  • Methylprednisolone 1 mg/kg/day has shown efficacy in dengue-associated refractory thrombocytopenia 2, 5, 6
  • Eltrombopag (thrombopoietin receptor agonist) can be added if severe bleeding occurs with refractory thrombocytopenia 2
  • This combination resulted in platelet recovery within 4 days in a case of dengue with refractory thrombocytopenia 2

Important caveat: Corticosteroids should only be considered for persistent thrombocytopenia in the recovery phase (after day 10), not during acute/critical phase, as they may worsen viral replication 5, 6.

Critical Pitfalls to Avoid

  1. Do not dismiss dengue based on IgG-only positivity: Secondary dengue infections show early IgG rise, and IgM may be delayed or absent 2, 3

  2. Do not assume typical dengue presentation: Dengue can present with severe CNS involvement (encephalitis) even without classic plasma leakage 2, 4

  3. Do not delay lumbar puncture: Normal inflammatory markers (ESR, CRP) do not exclude encephalitis; CSF analysis is essential 1

  4. Do not over-transfuse platelets: Prophylactic transfusion is not indicated unless counts are critically low or bleeding occurs 7

  5. Do not use corticosteroids in acute phase: Reserve steroids for refractory thrombocytopenia in recovery phase only 2, 5

Expected Clinical Course

  • Dengue encephalitis: Develops during critical phase (days 3-7), with only partial neurological recovery expected over weeks to months 2
  • Thrombocytopenia: Should resolve by day 10 in typical dengue; persistence beyond this suggests immune-mediated destruction requiring steroid therapy 5, 6, 8
  • Mortality risk: Severe dengue with encephalitis carries significant mortality (22.47% in severe dengue cohort), primarily from multiple organ dysfunction syndrome 3

References

6
Research

Steroid responsive prolonged thrombocytopenia in dengue.

Indian journal of medical sciences, 2010

Related Questions

How should I manage a 53-year-old man with a 7‑day history of fever (now resolved), sore throat, cough with whitish sputum, neutrophilic leukocytosis, thrombocytopenia with elevated MPV, dengue NS1 positive and IgG positive (secondary dengue), normal oxygen saturation, tachycardia, and hypertension treated with telmisartan?
In a 36‑year‑old woman with four days of fever, chills, and headache, leukopenia, mild thrombocytopenia, neutrophil 64.7 % and lymphocyte 24.5 % after two days of field work, and pending dengue serology, what is the most likely diagnosis and the appropriate treatment regimen with dosages?
In a 13‑year‑old on day 6 of the febrile phase of dengue with severe thrombocytopenia, leukopenia, normal hematocrit, brief upper‑extremity stiffening (possible seizure) without loss of consciousness, minimal hematemesis, stable blood pressure, and adequate urine output while receiving hydration, what is the appropriate immediate management?
In a patient with dengue fever and severe thrombocytopenia, what investigations and severity scores should be performed?
In a 13-year-old female with confirmed dengue (NS1 positive, IgM and IgG negative) on day 4 of fever, who is afebrile, has stable vital signs, leukopenia, normal hematocrit, and thrombocytopenia, what is the appropriate management and expected disease course?
How should I evaluate and manage a patient on risperidone who reports feeling tense?
How should serum C-reactive protein (CRP) be used to diagnose and manage infection in adult patients?
What is the standard initial work‑up and first‑line therapy for a newly diagnosed adult with non‑Hodgkin lymphoma?
What is the appropriate management for a patient with a bullous skin infection and an elevated C-reactive protein of 60 mg/L?
For a patient with isolated abdominal pain, should a chest computed tomography (CT) be added to the ordered abdomen and pelvis CT?
What is the recommended treatment protocol for amblyopia in children, including refractive correction, occlusion therapy, and atropine penalization?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.